Your browser doesn't support javascript.
loading
Melatonin supplementation in the subacute phase after ischemia alleviates postischemic sleep disturbances in rats.
Hao, Shu-Mei; Zhong, Zhi-Gang; Qu, Wei-Min; Huang, Zhi-Li; Sun, Feng-Yan; Qiu, Mei-Hong.
Afiliação
  • Hao SM; Department of Neurobiology, Institute for Basic Research on Aging and Medicine, School of Basic Medical Science, Fudan University, Shanghai, China.
  • Zhong ZG; Department of Neurobiology, Institute for Basic Research on Aging and Medicine, School of Basic Medical Science, Fudan University, Shanghai, China.
  • Qu WM; Department of Pharmacology, School of Basic Medical Science, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.
  • Huang ZL; Department of Pharmacology, School of Basic Medical Science, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.
  • Sun FY; Department of Pharmacology, School of Basic Medical Science, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.
  • Qiu MH; Department of Neurobiology, Institute for Basic Research on Aging and Medicine, School of Basic Medical Science, Fudan University, Shanghai, China.
Brain Behav ; 11(10): e2366, 2021 10.
Article em En | MEDLINE | ID: mdl-34520636
ABSTRACT

BACKGROUND:

Sleep disorders are highly prevalent among stroke survivors and impede stroke recovery. It is well established that melatonin has neuroprotective effects in animal models of ischemic stroke. However, as a modulator of endogenous physiological circadian rhythms, the effects of melatonin on poststroke sleep disorders remain unclear. In the present study, we investigated how melatonin delivered intraperitoneally once daily in the subacute phase after stroke onset, influencing neuronal survival, motor recovery, and sleep-wake profiles in rats.

METHODS:

Transient ischemic stroke in male Sprague-Dawley rats was induced with 30 min occlusion of the middle cerebral artery. Melatonin or vehicle was delivered intraperitoneally once daily in the subacute phase, from 2 to 7 days after stroke. Electroencephalogram and electromyogram recordings were obtained simultaneously.

RESULTS:

Compared to the effects observed in the vehicle-treated ischemic group, after 6 daily consecutive treatment of melatonin at 10 mg/kg starting at ischemic/reperfusion day 2, the infarct volume was significantly decreased (from 39.6 to 26.2%), and the degeneration of axons in the ipsilateral striatum and the contralateral corpus callosum were significantly alleviated. Sensorimotor performances were obviously improved as evidenced by significant increases in the latency to falling off the wire and in the use of the impaired forelimb. In addition to those predictable results of reducing brain tissue damage and mitigating behavioral deficits, repeated melatonin treatment during the subacute phase of stroke also alleviated sleep fragmentation through reducing sleep-wake stage transitions and stage bouts, together with increasing stage durations. Furthermore, daily administration of melatonin at 9 a.m. significantly increased the nonrapid eye movement sleep delta power during both the light and dark periods and decreased the degree of reduction of the circadian index.

CONCLUSIONS:

Melatonin promptly reversed ischemia-induced sleep disturbances. The neuroprotective effects of melatonin on ischemic injury may be partially associated with its role in sleep modulation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos do Sono-Vigília / Melatonina Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos do Sono-Vigília / Melatonina Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article